DICE Therapeutics, Inc.
DelistedCIK 1645569fmd_06TQVGR87FCHHFPAXRDXVVMQANManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Jun 30, 2023, 14 periods
| Line item | FY2020 | FY2021 | FY2022 |
|---|---|---|---|
| Total revenues | 1 | 1 | – |
| Research and development | 20 | 37 | 63 |
| Total operating expenses | 25 | 49 | 88 |
| Operating income | (24) | (48) | (88) |
| Interest expense | 0 | 0 | – |
| Net income | (24) | (49) | (84) |